FindTrial
Sign In

Role of dexmedetomidineas an analgesic in muscle pain in electro convulsive therapy

Role of dexmedetomidine in succinylcholine induced muscle soreness in electro convulsive therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037656
Enrollment
100
Registered
2021-10-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F20-F29- Schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders

Interventions

Intervention1: dexmedetomidine: IV dexmedetomidine 0.25 µg/kg diluted in normal saline (0.9%) to make a volume of 10 ml given over 10 minutes. Control Intervention1: placebo: IV normal saline (0.9%) 1

Sponsors

IMS AND SUM HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA-1, 2, age 18 - 65 years, Electroconvulsive therapy.

Exclusion criteria

Exclusion criteria: ASA- Class 3 or higher, uncontrolled hypertension, patients with a poor cardiopulmonary reserve and with body mass index (BMI) >30 kg/m2, renal failure, decompensated cirrhosis, being pregnant, or refusal to provide written informed consent

Design outcomes

Primary

MeasureTime frame
patient’s self-reported myalgia scores post ECT visual analog scale. Timepoint: 30 min, 1 hour,2 hour,6 hour ,12 hour—

Secondary

MeasureTime frame
o examine presence of any bradycardia and hypotension. Timepoint: 0,1,5,10,30,60 minutes—

Countries

India

Contacts

Public ContactDr BHAVNA SRIRAMKA

IMS AND SUM HOSPITAL

bhavna.sriramka@gmail.com7751007807

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026